
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx Inc has demonstrated strong expansion in its operational footprint, achieving an increase to 240 active implanting centers, reflecting a sequential growth of 13 centers. The company's total operating expenses rose approximately 8% year-over-year to $25.8 million, primarily due to a 11% increase in selling, general, and administrative expenses, which reached $23.4 million. This growth in implanting centers and the reinvestment in operational capabilities signify a commitment to expanding market reach and support for its proprietary Barostim technology, potentially positioning the company for sustained revenue growth in the cardiovascular medical device sector.
Bears say
CVRx Inc has revised its fiscal year 2025 revenue guidance to a range of $55.0 to $57.0 million, reflecting a modest growth projection of approximately 7-11% year-over-year, which is a reduction from the previous guidance range. Furthermore, the company has also lowered its revenue estimate for 2026 to $67.6 million from $74.1 million, indicating expectations of a moderated growth ramp in the U.S. market. Despite maintaining a gross margin of approximately 84% in the second quarter of 2025, these downward adjustments in revenue projections signal potential challenges in achieving growth targets, contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares